Clinical

Articles

Treatment with trastuzumab, pertuzumab, and docetaxel appears to yield similar efficacy to trastuzumab emtansine in patients with ErbB2-positive breast cancer.

Trastuzumab, Pertuzumab, and Docetaxel Treatment Comparable With T-DM1 in ErbB2+ Breast Cancer

The combination of trilaciclib plus chemotherapy has been granted a fast track designation by the FDA for the treatment of locally advanced metastatic triple-negative breast cancer.

FDA Grants Trilaciclib Plus Chemotherapy Fast Track Designation for Locally Advanced or Metastatic TNBC

The FDA supported Athenex to continue developing oral paclitaxel and encequidar for patients with metastatic breast cancer.

Athenex Discusses Deficiencies of Oral Paclitaxel Plus Encequidar for Metastatic Breast Cancer in FDA Type A Meeting

Patients who discontinued endocrine therapy early were more likely to have experienced significant mental, physical, and social adverse effects of treatment. 


Early Endocrine Therapy Discontinuation Linked to Certain Baseline Well-Being Factors

Differences in frequency of germline pathogenic variants were not seen in patient subsets by ethnicity when comparing 12 genes linked with breast cancer. 

Black and non-Hispanic White Women Found to Have No Differences in Genetic Risk for Breast Cancer

Approximately 270,000 women are diagnosed with breast cancer each year in the United States alone. While there is consensus among national organizations including the US Preventive Services Task Force, the American Cancer Society, and the American College of Radiology that routine mammography screening should be performed in women 50 years and older, there is debate about the benefit-to-harm ratio of routine screening in average-risk women aged between 40 and 49 years. In this review, we examine risks and benefits of routine breast cancer screening starting at age 40 at the individual level, followed by evaluation of the role of advanced imaging techniques in screening women on a population level.

Routine Breast Cancer Screening in Average-Risk Women Younger Than  50 Years: Current Paradigms  Based on National Guidelines

Patients who received breast-conserving surgery followed by radiotherapy demonstrated superior outcomes compared with patients who received mastectomy, regardless of radiotherapy status. 

Breast-Conserving Surgery With Radiotherapy Demonstrates Superiority Over Mastectomy in Breast Cancer

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.

Ultralow Risk 70-Gene Signature May Indicate Survival Outcomes in Early-Stage Breast Cancer 

Venetoclax plus fulvestrant did not result in better outcomes compared to fulvestrant alone in previously treated patients who had locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Venetoclax Plus Fulvestrant Did Not Improve Outcomes Compared to Fulvestrant Alone in ER+/HER2- Breast Cancer 

Palbociclib plus fulvestrant maintained a clinically meaningful overall survival improvement compared to placebo plus fulvestrant after a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.

Breast Cancer | Topics